FogPharma Collaborates with ARTBIO to Co-Develop Radiopharmaceutical Cancer Therapies

In The News
May 15, 2024

Ropes & Gray advised FogPharma in a collaboration with ARTBIO to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform, designed to better bind to solid tumor cancer targets and block harmful cellular signals with ARTBIO’s radiopharmaceutical AlphaDirect platform, designed to delivery radiation precisely into tumors. The collaboration seeks to produce a new category of targeted therapy on cancer cells. The transaction was announced on May 14.

The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associates Dan Freshman and Catherine Choi.